cc-diagnostics.com Open in urlscan Pro
2a01:4f8:c012:64d2::100  Public Scan

Form analysis
1 forms found in the DOM

GET https://cc-diagnostics.com/

<form role="search" method="get" id="searchform" class="searchform" action="https://cc-diagnostics.com/">
  <div>
    <label class="screen-reader-text" for="s">Zoeken naar:</label>
    <input type="text" value="" name="s" id="s">
    <input type="submit" id="searchsubmit" value="Zoeken">
  </div>
</form>

Text Content

 * Homepage
 * Management
 * Technology
 * News
 * Partners
 * Contact

Selecteer een pagina


DEVELOPING EARLY STAGE CERVICAL CANCER DIAGNOSTICS BASED ON NOVEL EPIGENETIC
MARKERS

Read more about the technology


CC DIAGNOSTICS RECOGNISES THE PREVENTABILITY OF CERVICAL CANCER IN WOMEN

Cervical cancer is a worldwide problem, but with regular and decent screening it
is mostly preventable since  with regular screening, the early precancerous
changes in cervical cells can be detected and treated. We have the goal to
improve this screening by making it more accurate and easier for women to
participate.





NOVEL METHYLATION TEST KIT FOR THE EPIGENETIC DETECTION OF EARLY STAGE CERVICAL
CANCER

We are going to do this by implementing a new diagnostic test aiming at
methylated genes, making use of PCR-technology. This test will replace the
current triage test, the PAP-test. The methylation test is more accurate,
bringing missed cancer cases from 24% to 3%, and reducing false-positives which
would save €2.9M in yearly healthcare costs in the Netherlands alone.


w

DEVELOPMENT

For the development of the test kit, CC Diagnostics works in cooperation with
partners specialised in technical kit development, assay validation, clinical
trials and performing pilot tests.



MANAGEMENT

The management team of CC Diagnostics consists of Ronald Vos (CEO) and Nutte van
Belzen (CMO).


RECENT NEWS


CC DIAGNOSTICS AND PARTNERS RECEIVE 600K SNN-EFRO SUBSIDY

26 april, 2024 | News

Currently, cervical cancer screening is inefficient and women-unfriendly. Every
year, one million European women receive an incorrect diagnosis, meaning that
expensive follow-up tests (such as colposcopy and biopsies)are unnecessarily
performed in hospitals. The...

Lees meer


DIAGNOSTISCHE TEST VOOR SCREENING BAARMOEDERHALSKANKER

19 juni, 2020 | News

Ontvangt subsidie voor de volgende activiteit(en): Nieuwe diagnostische test
baarmoederhalskanker screening – Methica CC kit Baarmoederhalskanker is een
ziekte die bijna altijd is te voorkomen door adequate screening. De huidige
screeningsmethoden zijn echter...

Lees meer


SNN/EFRO, PARTNER OF CC-DIAGNOSTICS

20 juni, 2019 | News

The project of CC Diagnostics has received help and funding from the Europees
Fonds voor Regionale Ontwikkeling (EFRO) in collaboration with
Samenwerkingsverband Noord-Nederland (SNN).  

Lees meer
« Vorige Pagina


PAGES

 * Homepage
 * Management
 * Technology
 * News
 * Partners
 * Contact

SEARCH

Zoeken naar:

CONTACT

E-mail: info@cc-diagnostics.com

CC DIAGNOSTICS

CC Diagnostics develops early stage cervical cancer diagnostics, based on novel
epigenetic markers.

 * Facebook

© 2024 CC Diagnostics | Powered by BRISP